312 related articles for article (PubMed ID: 32804298)
41. Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein.
Ito Y; Yamasaki K; Iwahara J; Terada T; Kamiya A; Shirouzu M; Muto Y; Kawai G; Yokoyama S; Laue ED; Wälchli M; Shibata T; Nishimura S; Miyazawa T
Biochemistry; 1997 Jul; 36(30):9109-19. PubMed ID: 9230043
[TBL] [Abstract][Full Text] [Related]
42. Assignments of backbone ¹H, ¹³C and ¹⁵N resonances in H-Ras (1-166) complexed with GppNHp at physiological pH.
O'Connor C; Kovrigin EL
Biomol NMR Assign; 2012 Apr; 6(1):91-3. PubMed ID: 21814767
[TBL] [Abstract][Full Text] [Related]
43. K-Ras prenylation as a potential anticancer target.
Baranyi M; Buday L; Hegedűs B
Cancer Metastasis Rev; 2020 Dec; 39(4):1127-1141. PubMed ID: 32524209
[TBL] [Abstract][Full Text] [Related]
44. Membrane-Driven Dimerization of the Peripheral Membrane Protein KRAS: Implications for Downstream Signaling.
Lee KY
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473778
[TBL] [Abstract][Full Text] [Related]
45. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
46. NMR Detection Methods for Profiling RAS Nucleotide Cycling.
Killoran RC; Smith MJ
Methods Mol Biol; 2021; 2262():169-182. PubMed ID: 33977476
[TBL] [Abstract][Full Text] [Related]
47. K-Ras Populates Conformational States Differently from Its Isoform H-Ras and Oncogenic Mutant K-RasG12D.
Parker JA; Volmar AY; Pavlopoulos S; Mattos C
Structure; 2018 Jun; 26(6):810-820.e4. PubMed ID: 29706533
[TBL] [Abstract][Full Text] [Related]
48. Molecular Basis for Allosteric Inhibition of GTP-Bound H-Ras Protein by a Small-Molecule Compound Carrying a Naphthalene Ring.
Matsumoto S; Hiraga T; Hayashi Y; Yoshikawa Y; Tsuda C; Araki M; Neya M; Shima F; Kataoka T
Biochemistry; 2018 Sep; 57(36):5350-5358. PubMed ID: 30141910
[TBL] [Abstract][Full Text] [Related]
49. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
50. Multivalent Small-Molecule Pan-RAS Inhibitors.
Welsch ME; Kaplan A; Chambers JM; Stokes ME; Bos PH; Zask A; Zhang Y; Sanchez-Martin M; Badgley MA; Huang CS; Tran TH; Akkiraju H; Brown LM; Nandakumar R; Cremers S; Yang WS; Tong L; Olive KP; Ferrando A; Stockwell BR
Cell; 2017 Feb; 168(5):878-889.e29. PubMed ID: 28235199
[TBL] [Abstract][Full Text] [Related]
51. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.
Schulze CJ; Seamon KJ; Zhao Y; Yang YC; Cregg J; Kim D; Tomlinson A; Choy TJ; Wang Z; Sang B; Pourfarjam Y; Lucas J; Cuevas-Navarro A; Ayala-Santos C; Vides A; Li C; Marquez A; Zhong M; Vemulapalli V; Weller C; Gould A; Whalen DM; Salvador A; Milin A; Saldajeno-Concar M; Dinglasan N; Chen A; Evans J; Knox JE; Koltun ES; Singh M; Nichols R; Wildes D; Gill AL; Smith JAM; Lito P
Science; 2023 Aug; 381(6659):794-799. PubMed ID: 37590355
[TBL] [Abstract][Full Text] [Related]
52. Covalent targeting of acquired cysteines in cancer.
Visscher M; Arkin MR; Dansen TB
Curr Opin Chem Biol; 2016 Feb; 30():61-67. PubMed ID: 26629855
[TBL] [Abstract][Full Text] [Related]
53. Identification of pyrazolopyridazinones as PDEδ inhibitors.
Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
[TBL] [Abstract][Full Text] [Related]
54. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
55. Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.
Spencer-Smith R; Li L; Prasad S; Koide A; Koide S; O'Bryan JP
Small GTPases; 2019 Sep; 10(5):378-387. PubMed ID: 28692342
[TBL] [Abstract][Full Text] [Related]
56. KRAS
Cagir A; Azmi AS
Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
[No Abstract] [Full Text] [Related]
57. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
58. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.
Hamilton G; Plangger A
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1065-1074. PubMed ID: 34347509
[TBL] [Abstract][Full Text] [Related]
59. High-throughput, single-particle tracking reveals nested membrane domains that dictate KRas
Lee Y; Phelps C; Huang T; Mostofian B; Wu L; Zhang Y; Tao K; Chang YH; Stork PJ; Gray JW; Zuckerman DM; Nan X
Elife; 2019 Nov; 8():. PubMed ID: 31674905
[TBL] [Abstract][Full Text] [Related]
60. Structures of RGL1 RAS-Association Domain in Complex with KRAS and the Oncogenic G12V Mutant.
Eves BJ; Gebregiworgis T; Gasmi-Seabrook GMC; Kuntz DA; Privé GG; Marshall CB; Ikura M
J Mol Biol; 2022 May; 434(9):167527. PubMed ID: 35257782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
